Search for a trial

Single Blind Randomized Phase III Trial to Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer

- Primary study objective: To demonstrate the superiority of the ablative microboost dose schedule regarding 5-year biochemical no evidence of disease rate compared to the current standard of care.- Secondary study objectives: Establish and compare…

Validation and standardization of the measurement of pelvic floor dysfunction with the MAPLE-probe

A. Determine the placement of the Maple-probe in relation to the anatomy of the pelvic floor musculature.B. Determine the normal rest tone of the pelvic floor musculatureC. Determine the normal activity of the pelvic floor musculatureD. Determine…

A randomised controlled trail comparing the TVT-O® with the Ajust® as primary surgical treatment of female stress urinary incontinence.

Objective: Primary Objective: to compare the immediate and postoperative pain (up to 6 weeks) between the Ajust® and TVT-O® proceduresSecondary Objective(s): 1. Objective cure of the SUI at 6 and 12 months follow up2. Subjective cure and improvement…

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus
Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men
With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive
Therapy.

This study has been transitioned to CTIS with ID 2024-513521-23-00 check the CTIS register for the current data. All efficacy and safety objectives will compare enzalutamide plus leuprolide and enzalutamide monotherapyversus placebo plus leuprolide.

Two-fraction Ultra-hypofractionated Radiotherapy with Focal Boost for low- and intermediate risk, localized prostate cancer (TURBO):phase II, randomized controlled clinical trial

To assess non-inferiority of treating patients with localized, intermediate risk prostate cancer in two fractions of 12 Gray (Gy) with a boost to the gross tumor volume of 13.5 Gy per fraction in 8 days, as compared to standard care (36.25 Gy in…